ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

Based on its selective targeting of toxic Aβ oligomers and the ... misfolding-specific monoclonal antibodies and intrabodies against a pathogenic loss-of-structure epitope in the N-terminal ...

"The decrease in motivation to implement lifestyle changes after the disclosure of elevated or nonelevated Aβ status warns against false reassurance during the disclosure process." HealthDay News ...

CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...

The team used these chemical groups to attach vitamin D-binding antibodies to the MXene surface. "Combining MXenes with antibodies resulted in a very sensitive and highly selective material for ...

This fundamental study explores a novel cellular mechanism underlying the degeneration of locus coeruleus neurons during chronic restraint stress. The evidence supporting the overexpression of LC ...

Generate Bio uses a combination of sequence and structure-based approach towards de novo design of a variety of proteins, including antibodies with desired properties. In addition to its ...

Figure 1: The site on HIV-1 gp120 (gray) of interaction with the CD4 receptor (yellow) represents a conserved accessible surface on HIV-1, and many commonly elicited antibodies compete with CD4 ...

An elevated Aβ disclosure showed a modest decrease in anxiety and motivation to change lifestyle. HealthDay News — Disclosure of amyloid-β (Aβ) status seems not have a negative psychological ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.